Senate Health Panel to Vote on Subpoena for Novo Nordisk Over Drug Prices

Bernie Sanders leads charge to question high U.S. costs for Ozempic and Wegovy compared to international prices.

The Senate Committee on Health, Education, Labor, and Pensions will vote on June 18 regarding a subpoena for Novo Nordisk executive Doug Langa.
Sanders' investigation revealed U.S. prices for Ozempic and Wegovy are significantly higher than in other countries.
Novo Nordisk claims cooperation with the committee and questions the necessity of a subpoena.
Previous similar tactics by Sanders have led to voluntary testimonies from pharmaceutical executives.
The high demand for these drugs has sparked a broader debate on drug pricing and market dynamics.